Novartis Buys Rights to Intecell's Japanese Encephalitis Vaccine Candidate
Filed in archive Corporate and Industrial News , Drugs, Vaccines and Therapeutics by ruth on June 14, 2006

Intercell recently announced favorable results for IC51 in Phase III clinical trials and the vaccine is currently under regulatory review in Europe with an orphan drug status.
Further details from Market Watch.
Permalink: Novartis Buys Rights to Intecell's Japanese Encephalitis Vaccine Candidate
Tags:
vaccine encephalitis biotech novartis rights japanese+encephalitis vaccine+candidate novartis+buys
Trackback: http://www.creative-weblogging.com/cgi-bin/mt-tb.pl/24761















